tbuckley/cabot-search huggingface dataset:
FRI0703-HPR INVESTIGATION OF THE EFFECTIVENESS OF AEROBIC EXERCISE TRAINING IN INDIVIDUALS WITH ANKYLOSING SPONDYLITIS: RANDOMIZED CONTROLLED STUDY
Authors: Bilge Basakci Calik, Mine Pekesen Kurtca, Elif Gur Kabul, Orcin Telli Atalay, Harun Taskın, Murat Yigit, Murat Tascı, Veli Cobankara
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Aerobic capacity is a measure of the functional capacity of the oxygen system and the cardiopulmonary system. In Ankylosing spondylitis(AS) patients, aerobic capacity is lower than healthy peers, and this is due to inflammation, muscle atrophy and peripheral muscle weakness, fatigue, low physical activity level, negatively affected respiratory function, peripheral arthritis, decreasing chest expansion and respiratory muscle strength. <h3>Objectives</h3> The aim of the study was to investigate the effects of aerobic exercise training on functional status and aerobic capacity in individuals with AS. <h3>Methods</h3> Twenty-eight voluntary individuals diagnosed with AS according to Modifie New York Criteria who applied to Pamukkale University Department of Internal Medicine, Department of Rheumatology were included in the study. Individuals were randomly divided into two groups, as there would be aerobic exercise training (n=17; mean age=46.58±11.94years) and supervised exercises group (n=11; mean age=42.54±8.75years). All assessments were done before and after the training. After the demographic characteristics and disease related data of the individuals were recorded; for the functional status, the Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Metrology Index (BASMI) were used. Six-minute walk test(6MWT) was used for the assessment of aerobic capacity. Group I was attended 40 min aerobic exercises sessions (5-min warm up, 30-min treadmil, 5-min cool down), plus supervised spinal mobilite exercises and Group II was attended only supervised spinal mobilite exercises per day, 3 times a week, for 12 weeks. Data were analysed Wilcoxan and Mann Whitney U Test. <h3>Results</h3> After training aerobic exercise group, BASMI (p=.021), BASDAI (p=.002) and 6MWT(p=.036) results were statistically significant, while the difference was not significant in BASFI (p=.068). It was observed that there was no significant difference in the after training period in the supervised exercises group. BASDAI, in group aerobic exercise group had improved more significantly when compared to supervised exercises group. <h3>Conclusion</h3> As a result of the study, it was noted that when aerobic exercise training applied together with the supervised exercises in ankylosing spondylitis patients, effectiveness on mainly disease activity, spinal mobility and aerobic capacity was increased. Key words: Ankylosing spondylitis, aerobic exercise training, supervised exercised. <h3>References</h3> [1] Pulmonary System Lımıtatıons To Endurance Exercıse PerformanceInHumans. Exp Physiol. 2012;97(3):311–318. <h3>Disclosure of Interests</h3> None declared
SP0123 NEW TREATMENTS: WHY SHOULD WE WAIT?
Authors: Daniel Morales
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Improving access to new and established medicines for rheumatological disease is of public health importance. However, drug development processes, medicines regulation and health technology requirements may significantly impact on when a new medicine become available to be used by health care professionals. <h3>Objectives:</h3> The objectives of this session are to present some of the challenges and opportunities for accessing new and established medicines for rheumatological disease. <h3>Methods:</h3> Drug development processes, medicines regulation and health technology requirements may significantly impact on when a new medicine become available to be used by health care professionals. Although these requirements may be perceived as barriers, many of these requirements are in place to ensure a medicines benefit risk profile is favorable and is cost effective in terms of quality of life. This session will briefly discuss issues around the process of making medicines newly available from drug development to gaining new market approvals with an emphasis on rheumatological disease, including the post-authorization safety requirements that are in place to safe guard public health. <h3>Disclosure of Interests:</h3> None declared
Sixty seconds on . . . fortified flour
Authors: Gareth Iacobucci
Journal: BMJ (2019)

It would seem so. The UK government has announced a consultation1 on introducing mandatory fortification of flour with folic acid to help reduce neural tube defects in babies, by raising the folate levels of women who could become pregnant.

The UK currently has 1000 diagnoses of neural tube defects such as spina bifida and anencephaly every year, and evidence …
Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease
Authors: Jens Drube, Mandy Wan, Marjolein Bonthuis, Elke Wühl, Justine Bacchetta, Fernando Santos, Ryszard Grenda, Alberto Edefonti, Jerome Harambat, Rukshana Shroff, Burkhard Tönshoff, Dieter Haffner
Journal: Nature Reviews Nephrology (2019)

Achieving normal growth is one of the most challenging problems in the management of children with chronic kidney disease (CKD). Treatment with recombinant human growth hormone (GH) promotes longitudinal growth and likely enables children with CKD and short stature to reach normal adult height. Here, members of the European Society for Paediatric Nephrology (ESPN) CKD–Mineral and Bone Disorder (MBD), Dialysis and Transplantation working groups present clinical practice recommendations for the use of GH in children with CKD on dialysis and after renal transplantation. These recommendations have been developed with input from an external advisory group of paediatric endocrinologists, paediatric nephrologists and patient representatives. We recommend that children with stage 3–5 CKD or on dialysis should be candidates for GH therapy if they have persistent growth failure, defined as a height below the third percentile for age and sex and a height velocity below the twenty-fifth percentile, once other potentially treatable risk factors for growth failure have been adequately addressed and provided the child has growth potential. In children who have received a kidney transplant and fulfil the above growth criteria, we recommend initiation of GH therapy 1 year after transplantation if spontaneous catch-up growth does not occur and steroid-free immunosuppression is not a feasible option. GH should be given at dosages of 0.045–0.05 mg/kg per day by daily subcutaneous injections until the patient has reached their final height or until renal transplantation. In addition to providing treatment recommendations, a cost-effectiveness analysis is provided that might help guide decision-making. This Evidence-Based Guideline developed by members of the European Society for Paediatric Nephrology CKD-MBD, Dialysis and Transplantation working groups presents clinical practice recommendations for the use of growth hormone in children with chronic kidney disease on dialysis and after renal transplantation.
Gut microbiome and kidney stone disease: not just an Oxalobacter story
Authors: Andrea Ticinesi, Antonio Nouvenne, Tiziana Meschi
Journal: Kidney International (2019)

Intestinal regulation of oxalate absorption is a complex mechanism, not exclusively reliant on the oxalate-degrading anaerobe Oxalobacter formigenes. Using metagenomics, Miller et al. were able to describe a network of bacterial taxa co-occurring with Oxalobacter formigenes in fecal samples from non-stone forming controls and less represented in stone formers. These findings may help to illuminate why previous intervention studies with probiotics have failed to reduce the risk of hyperoxaluria, opening new possibilities for future research.
FRI0273 SURVEYING PATIENTS WITH TAKAYASU ARTERITIS WITH A DELAYED DIAGNOSIS
Authors: Irina Borodina, Artem Popov
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Takayasu arteritis (TA) is a well known, but rarely identified variety of large vessel vasculitis. Frequency of initial misdiagnosing in TA patients has been reported to reach 80%. Up to 80% of TA cases are correctly diagnosed only 2 to 11 years after the symptoms presentation. Objectives: to study possible reasons for misdiagnosing in TA patients with a delayed diagnosis. Methods: cross-sectional survey included 30 TA patients. All subjects met ACR criteria for TA and more than 12 months since the onset of the clinical manifestations delayed diagnosis. The subjects were asked to recall if vessels auscultation (VA), measurement of both arms and legs blood pressure (BP), assessment of BP and pulse asymmetry (PA) were performed during their first physician visit following the symptoms onset. <h3>Results</h3> 19 (67%) patients reported no VA during the initial examination, only 3 (10%) subjects confirmed the test performed, 5 (17%) were not sure and 3 (10%) did not apply for medical aid during the first year of the symptoms occurrence. Arms BP asymmetry was not assessed in 13 (43%) patients, in 6 (20%) subjects correct BP tests were performed, 8 (27%) responders were not sure and 3 (10%) had not consulted any physician timely. PA was assessed in7 (23%) cases, PA was not tested in 12 (40%) patients, and 8 (27%) subjects were not sure. Arms and legs BP was not assessed in 26 (87%) patients during their initial examination. Conclusion: the data obtained confirm paramount importance of proper physical examination during initial physician's consultation for timely and correct Takayasu arteritis diagnosis. <h3>References</h3> [1] Arend W.P., Michel B.A., Bloch D.A., et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990; 33(8): 1129-1134. [2] Pokrovskiĭ AV, Zotikov AE, Kul'bak VA, Burtseva EA. Problems of diagnostics and treatment strategy in patients with Takayasu' arteries. Vestn Ross Akad Med Nauk. 2010;(10):9-19. [3] Ringleb PA, Strittmatter EI, Loewer M, et al. Cerebrovascular manifestations of Takayasu Arteritis in Europe. Rheumatology2005; 44 (8): 1012–5. <h3>Acknowledgement</h3> accept <h3>Disclosure of Interests</h3> None declared
Tailoring the lipid composition of nanoparticles modulates their cellular uptake and affects the viability of triple negative breast cancer cells
Authors: Hanan Abumanhal-Masarweh, Dana da Silva, Maria Poley, Assaf Zinger, Evgenya Goldman, Nitzan Krinsky, Ron Kleiner, Gal Shenbach, Josh E. Schroeder, Jeny Shklover, Janna Shainsky-Roitman, Avi Schroeder
Journal: Journal of Controlled Release (2019)
PF316 THE CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH AGGRESSIVE LARGE CELL LYMPHOMA AND DIABETES MELLITUS
Authors: O. Pasvolsky, A. akirov, B. elias, P. raanani, R. gurion, U. rozovski
Journal: HemaSphere (2019)

Background: Epidemiological studies suggest that patients with diabetes mellitus (DM) are at‐risk to develop several types of cancers, including non‐Hodgkin lymphoma. Whether DM affects the clinical presentation or outcome of patients with lymphoma is unknown. Since patients with DM are prone to develop infectious complications, we hypothesize that the co‐occurrence of DM would increase the rate and/or severity of infectious complications in patients with lymphoma who receive chemotherapy. Aims: To describe the clinical characteristics and outcomes of patients with DM who received treatment for aggressive large cell lymphoma. Methods: This is a single center retrospective single center study. We included all consecutive patients who were diagnosed with aggressive large cell lymphoma and were treated at our institute between 2013 and 2017. Demographics, disease‐related and outcome data were extracted from the electronic medical records. Additional data and lab results were extracted from the hospital database. Categorical variables were compared using the χ2 or the Fischer exact test, and Mann Whitney was used to compare medians. Results: Between the years 2013 and 2017 we treated 226 patients with aggressive large cell lymphoma, most (n = 219, 96%) with diffuse large B cell lymphoma. In this cohort 49 patients (22%) had type 2 DM. None of our patients had type 1 DM. The median age of patients with DM was 70 years, and of non‐DM patients 65 years (P = 0.001). Patients with DM tended to have higher baseline BMI values (P = 0.057), but were comparable in all other demographic characteristics. Likewise, response to therapy, relapse rates and survival outcomes were similar in patients with DM compared to non‐DM patients. There were 133 hospital admissions due to febrile neutropenia (FN) in the entire cohort. Patients with DM had higher rates of admissions due to FN (P = 0.004). The admission rate in patients with DM remained higher after age‐matched subgroup analysis (P = 0.005). Yet, the duration of hospitalizations and number of admissions to the ICU were similar in patients with or without DM. In patients with DM, improved glycemic control during FN hospitalizations was associated with shorter hospital duration (P = 0.007). However, Hemoglobin A1C levels were not associated with increased risk for FN or infectious complications. Summary/Conclusion: Patients with aggressive large cell lymphoma and DM have higher rates of hospitalizations due to FN. In this high risk population, perhaps more aggressive measures should be made to avoid infectious complications. Furthermore, our data suggests that improved glycemic control during hospitalization is associated with shorter length of hospitalization due to FN in patients with DM.
SWOG S0919: A phase II study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukemia (AML).
Authors: Anjali S. Advani, Shannon McDonough, Edward Copelan, Cheryl L. Willman, Deborah A. Mulford, Alan F. List, Mikkael A. Sekeres, Megan Othus, Harry P. Erba, Frederick R. Appelbaum
Journal: Journal of Clinical Oncology (2013)

7028 Background: Inhibition of cholesterol synthesis and uptake sensitizes AML blasts to chemotherapy (Blood 104: 1816, 2004). A prior Phase 1 study demonstrated the safety of high dose pravastatin given with idarubicin and cytarabine in patients with AML and also reported an encouraging response rate (Blood 109: 2999, 2007). SWOG S0919 therefore evaluated the complete remission (CR) rate in a larger number of pts with relapsed AML treated with the pravastatin dose arrived at in the Phase 1 trial. Methods: Pts were treated at SWOG institutions from Aug 2009 through Nov 2012. Pravastatin was supplied by Bristol-Meyers Squibb. The protocol was approved by each institution’s review board. Eligibility: age ≥ 18 yrs, relapsed AML, cardiac ejection fraction ≥ 45%, CR/ CR with incomplete count recovery (CRi) following most recent chemotherapy lasting ≥ 3 months, no prior hematopoietic cell transplant. Treatment: oral pravastatin 1280 mg Days 1-8, idarubicin 12 mg/m 2 /d IV Days 4-6, and cytarabine 1.5 g/m 2 /d continuous IV infusion Days 4-7. Pts achieving a CR could receive 2 cycles of consolidation. CR and CRi were defined by IWG criteria. Fifty eligible pts were to be accrued. If ≥ 21 pts achieved CR or CRi, the regimen would be considered sufficiently effective (critical level = 4.8% if true CR rate = 30% and power of 90% if true CR rate = 50%). Results: The study closed to accrual on Nov 1, 2012 after meeting the defined criterion for a positive study. Thirty-six pts with a median age of 59 yr (range 23-78) were enrolled. Seventeen pts (47%) were male and the median WBC was 2800/ uL (range 700-110,600). The median time from initial dx to registration was 18 mo (range 5-136). Relapse status: 1 st : 17 pts (47%), 2 nd : 15 (42%), 3 rd : 2 (5.5%), and 4 th : 2 (5.5%). Eighteen pts have died, 3 during treatment. The response rate was 75% (95% CI 58-88%; 20 CR, 7 CRi); and the median overall survival was 10 mo. The p-value comparing 75% to 30% (null response rate) is 3.356 x 10 -8 . Duration of last CR (≤ 6 months) and prior high dose cytarabine exposure did not affect response to protocol treatment. Conclusions: The CR/ CRi in this relapsed population is encouraging. We plan to evaluate the efficacy of this regimen in higher-risk patients. Clinical trial information: NCT00840177.
Maintenance of Fitness and Quality-of-Life Benefits From Supervised Exercise Offered as Supportive Care for Breast Cancer
Authors: Amy A. Kirkham, Kelcey A. Bland, Holly Wollmann, Alis Bonsignore, Don C. McKenzie, Cheri Van Patten, Karen A. Gelmon, Kristin Campbell
Journal: Journal of the National Comprehensive Cancer Network (2019)

Background: Overwhelming randomized controlled trial evidence demonstrates that exercise has positive health impacts during and after treatment for breast cancer. Yet, evidence generated by studies in which exercise programs are delivered outside a tightly controlled randomized trial setting is limited. The purpose of this study was to assess the effectiveness of an evidence-based exercise program with real-world implementation on physical fitness and quality of life (QoL). Patients and Methods: Oncologists referred women with early-stage breast cancer who were scheduled to receive adjuvant chemotherapy. The program consisted of supervised aerobic and resistance exercise of moderate to vigorous intensity 3 times per week until the end of treatment (chemotherapy ± radiotherapy), then twice per week for 10 weeks, followed by once per week for 10 weeks. Health-related physical fitness and QoL were assessed at baseline, end of treatment, end of program, and 1-year follow-up. Results: A total of 73 women were enrolled. Estimated peak VO 2 (VO 2 peak), QoL, and body weight were maintained between baseline and end of treatment, whereas muscular strength improved ( P &lt;.01). By the end of the program, VO 2 peak, heart rate recovery, waist circumference, and some aspects of QoL were improved (all P &lt;.01) relative to baseline. One year later, VO 2 peak, QoL, and waist circumference were maintained relative to end of program, whereas the improvements in strength and heart rate recovery had dissipated (all P &lt;.01). Conclusions: Evidence-based exercise programming delivered with real-world implementation maintained VO 2 peak, strength, and QoL during adjuvant treatment and improved these measures after treatment completion among women with breast cancer. Continued guidance and support may be required for long-term maintenance of strength improvements in this population.
Abstract 10727: CD44 Variant Appearing as a Result of Endothelial-Mesenchymal Transition Contributes to Pulmonary Vascular Remodeling of Pulmonary Arterial Hypertension
Authors: Sarasa Isobe, Masaharu Kataoka, Jin Endo, Yoshinori Katsumata, Tsunehisa Yamamoto, Kohsuke Shirakawa, Hidenori Moriyama, Keiichi Fukuda, Motoaki Sano
Journal: Circulation (2018)

Introduction: Pulmonary arterial hypertension (PAH) exhibits many features common to cancer cells, which offers the opportunity to exploit therapeutic strategies used in cancer to treat PAH. CD44 e...
PB1892 REAL WORLD TREATMENT PERSISTENCE OF NEW ZEALAND IBRUTINIB CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS IN A NAMED PATIENT PROGRAM
Authors: R. Weinkove, R. Doocey, R. Henderson, S. Islam, M. Smith, A. Puig, G. Pateman, M. Acar, C. Amaya‐Chanaga, D. Simpson
Journal: HemaSphere (2019)

Background: Named Patient Programs (NPPs) provide access to medicines in response to unsolicited requests by physicians for specific patients before they become commercially available. Janssen New Zealand opened a NPP for ibrutinib for patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) in September 2014. The program closed for new enrolments in April 2018, but enrolled patients have continued to receive treatment as of 7 th January 2019. Aims: To analyse duration on ibrutinib treatment for patients with relapsed/refractory CLL enrolled in a New Zealand NPP. Methods: A retrospective cohort analysis was conducted using data entered by treating physicians when enrolling patients into the NPP via the Janssen Managed Access Portal (MacWeb). At each resupply patients were provided with 3 months’ supply of ibrutinib. Patient time on treatment was estimated using fulfilled resupply requests submitted by physicians. Patients were considered to be on treatment until the date of last ibrutinib resupply, plus one month. A patient was considered discontinued based on physician declaration, or if no ibrutinib had been resupplied for four months or more. All other patients were censored at the reporting date of 7 th January 2019. This real‐world estimate of treatment duration was compared to time to treatment discontinuation in the ibrutinib arm of the RESONATE trial, as reported in Hillmen et al. EHA; 2016 (abstract 133196) and Tam et al. EHA; 2018 (abstract 214826). Time on treatment was evaluated using Kaplan‐Meier (KM) curves, and statistical testing was conducted using log‐rank testing. Results: 112 ibrutinib‐treated patients with CLL were included in the analysis. 59% of the population were male, 37% had 3 or more prior lines of therapy before commencing therapy, and 32% had refractory disease. 73% of patients were on therapy at 12 months (95% CI: 0.64‐0.8) and median time to discontinuation has not been reached at the time of the analysis. 42% of patients were estimated to have discontinued therapy over the 49‐month period. The comparison between patient time on treatment on the New Zealand NPP and the RESONATE trial were statistically not different (HR 1.01; 95% CI: 0.71‐1.44; p = 0.96). Summary/Conclusion: This real‐world analysis estimates that patient time on NPP treatment in New Zealand closely tracks time on treatment as observed in the RESONATE trial. While there are limitations to the NPP data as it was based on unmonitored physician declarations, and duration on treatment was estimated from resupply data, these findings suggest that duration of treatment in a New Zealand non‐trial setting is similar to that in the Phase 3 clinical trial. image
Dehydrocostus lactone as Cyclooxygenase-2 specific inhibitor
Authors: Feng Chen, Pang C. Shaw, Jun Wang
Journal: Cancer Research (2004)

1010  Cyclooxygenase-2 (COX-2) gene encodes an inducible enzyme that converts arachidonic acid to prostaglandins and is up-regulated in colorectal neoplasms. Large scale of retrospective and prospective studies has showed that COX-2 inhibitors decrease colorectal cancer incidence and mortality. The aim of this study is to determine whether dehydrocostus lactone purified from plant can act as the selective inhibitor and their potential use as new anti-cancer drugs. Dehydrocostus lactone is a sesquiterpene compound isolated from Sassurea lappa Clarks, which has been widely used as a medicinal plant in China, Korea and India. Our research shows that dehydrocostus lactone can inhibit PGE2 synthesis by 42% in vitro, comparing with a 33% inhibition by Indomethacin, using PGE2 specific Competitive Enzyme Immunoassay. The inhibition is specific as the chemical does not inhibit cyclooxygenase-1. In vivo study indicates that dehydrocostus lactone suppresses the growth of colorecral cancer xenografts transplanted by colon cancer cell line colo205 in athymic mice. The inhibition effect was dose dependent, with 18% reduction in 5mg/kg/day group, and 46% reduction in 10mg/kg/day (p